Duloxetine Capsule, Delayed Release
Product Images NDC 51407-810

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 51407-810). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51407-807-60lb (Duloxetine 20mg 60.jpg)

Label for Duloxetine delayed-release capsules, USP 20 mg by Golden State Medical Supply, Inc. The package contains 60 capsules for oral use. The label includes NDC 51407-807-60, directions for pharmacist, storage instructions, and marketing information referencing GSMS, Incorporated.*

FDA Label Image

51407-808-90lb (Duloxetine 30mg 90.jpg)

Label for Duloxetine delayed-release capsules, USP with a strength of 30 mg. The label includes the NDC number, dosage form, quantity of 90 capsules, and instruction to dispense the Medication Guide. It also provides storage and usage instructions, the manufacturer Golden State Medical Supply, Inc., and market origin information.*

FDA Label Image

51407-809-30lb (Duloxetine 40mg 30.jpg)

The label for Duloxetine Delayed-Release Capsules, USP, 40 mg, by Golden State Medical Supply, Inc. It indicates the product is a prescription drug containing 40 mg capsules, with a package size of 30 capsules. The label includes dosage, storage instructions, and manufacturer details, with a barcode and NDC 51407-809-30.*

FDA Label Image

51407-810-30lb (Duloxetine 60mg 30.jpg)

Label for Duloxetine Delayed-Release Capsules, USP 60 mg, oral capsules supplied by Golden State Medical Supply, Inc. The label shows a 30-capsule package with instructions for pharmacists, storage conditions, dosage guidance, and manufacturer details including GSMS, Inc., Camarillo, CA. The label includes a barcode and a QR code with batch information spaces.*

FDA Label Image

Image (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 942 1)

Duloxetine delayed-release capsules from Golden State Medical Supply, Inc. The image shows individual capsules in five different strengths: 20 mg, 30 mg, 40 mg, and 60 mg. Each capsule features distinctive color patterns including combinations of white, green, pink, and burgundy on a capsule-shaped form.*

FDA Label Image

Image (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 935 1)

Duloxetine delayed-release capsules in four strengths: 20 mg, 30 mg, 40 mg, and 60 mg. The image shows each capsule above its respective dosage in milligrams, arranged in a vertical sequence. The labeler displayed is Golden State Medical Supply, Inc.*

FDA Label Image

Structure (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 01)

Chemical structure of duloxetine hydrochloride showing atoms, bonds, and ring structures including a fused bicyclic aromatic system and a thiophene ring.*

FDA Label Image

Figure 1 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 02)

A Kaplan-Meier survival curve graph showing the proportion of patients with relapse over time (days) from randomization. The graph compares treatment with Duloxetine and Placebo, with Duloxetine represented by a solid line and Placebo by a dashed line. The y-axis represents the proportion of patients with relapse (0 to 1), and the x-axis shows time in days from 0 to 250.*

FDA Label Image

Figure 2 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 03)

A Kaplan-Meier curve comparing the proportion of patients with relapse over time (days) between Duloxetine and placebo treatments. The y-axis represents the proportion of patients with relapse, and the x-axis shows time from randomization to relapse in days. The graph illustrates lower relapse rates for Duloxetine compared to placebo throughout the study period.*

FDA Label Image

Figure 1 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 04)

A line graph depicting the percentage of patients improved at varying levels of percent improvement in pain from baseline. The lines represent Duloxetine 60 mg twice daily (BID), Duloxetine 60 mg once daily (QD), Duloxetine 20 mg once daily (QD), and Placebo, showing comparative effectiveness in pain improvement.*

FDA Label Image

Figure 2 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 05)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo, showing patient response levels across a range of pain improvement percentages.*

FDA Label Image

Fig 5 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 06)

A line graph comparing the percentage of patients improved against percent improvement in pain from baseline for Duloxetine 60 mg taken twice daily, Duloxetine 60 mg taken once daily, and placebo. The y-axis shows percentage of patients improved, and the x-axis shows percent improvement in pain, with data points illustrating patient response to different treatments.*

FDA Label Image

Fig 6 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 07)

A line graph illustrating the percentage of patients improved versus percent improvement in pain from baseline for different duloxetine dosages and placebo. The graph compares Duloxetine 120 mg twice daily, Duloxetine 60 mg once daily (two data sets), and a placebo group, showing trends of patient improvement over a range of pain reduction percentages.*

FDA Label Image

Fig 7 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 08)

A line graph shows the percentage of pediatric patients aged 13 to 17 with Juvenile Fibromyalgia Syndrome achieving various levels of pain relief at week 12 in Study FM-4. It compares pain improvement between Duloxetine 60 mg once daily and placebo, with the x-axis representing percent improvement in pain from baseline and the y-axis showing the percentage of patients improved. Two distinct trend lines illustrate greater pain relief with Duloxetine versus placebo.*

FDA Label Image

Figure 8 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 09)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily and placebo. The x-axis shows percent improvement in pain, ranging from >0 to 100, and the y-axis shows the percentage of patients improved, ranging from 0 to 100%. The Duloxetine line generally shows higher patient improvement percentages compared to placebo.*

FDA Label Image

Figure 9 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 10)

A line graph comparing the percentage of patients improved between placebo and Duloxetine 60 mg once daily. The x-axis shows percent improvement in pain from baseline (BOCF), ranging from greater than 0 to 100 percent. The y-axis shows the percentage of patients improved, ranging from 0 to 100 percent. Two lines plot patient improvement percentages for placebo and Duloxetine 60 mg, highlighting greater improvement with Duloxetine across different percent improvement thresholds.*

FDA Label Image

Figure 10 (B6b52b38 E1ac 4477 Ae44 Fa297b2a0db0 11)

A line graph comparing the percentage of patients improved against the percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily and placebo. The x-axis shows percent pain improvement ranging from >0 to 100, and the y-axis shows the percentage of patients improved from 0 to 100%. Two lines represent Duloxetine and placebo outcomes across the pain improvement spectrum.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.